The case for multi-target drugs: Curis

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Small molecule dual targeting inhibitors
Reply to topic
The case for multi-target drugs: Curis
hedgehog
Site Admin

Joined: 19 Jan 2006
Posts: 820
Location: Bay Area
Post Posted: Sun Jan 21, 2007 2:21 pm Reply with quote
Curis has developed a proprietary pipeline of drug programs based upon validated targets:

The case for multi-target drugs:

  • Heterogeneity of cells within tumors
  • Redundancy of proliferative and survival pathways
  • Potential synergies could lead to superior efficacy, which is expected to lead to reduced dosage and toxicity
  • Simultaneous inhibition of several cellular targets could reduce drug resistance in human malignancies


Here is a list of what is in the pipeline


_________________
Your complete guide for Hedgehog, BMP-7, and Curis information
~Enjoy your stay with us
View user's profileSend private messageSend e-mailMSN Messenger
The case for multi-target drugs: Curis
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Small molecule dual targeting inhibitors
 Reply to topic  
Forum Map
Site Map